Abdera is building a pipeline of potential best-in-class radiotherapeutics capable of delivering alpha- or beta-emitting radionuclide payloads to a broad range of emerging and clinically validated solid tumor targets.

Abdera is enrolling patients in a Phase 1 clinical of ABD-147 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). For additional information, please visit clinicaltrials.gov/study/NCT06736418.

Abdera is leveraging its proprietary ROVEr™ platform to engineer and develop new precision radiotherapeutics with tunable PK properties to maximize therapeutic effect while mitigating systemic toxicities in order to treat a broad range of solid tumors.

Jan 30, 2024 · Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Apr 20, 2023 · Abdera aims to optimize the therapeutic index of potent radioisotopes emitting alpha or beta particles to selectively destroy tumor cells while sparing healthy cells, providing patients with potentially transformative new cancer treatments.

Jun 27, 2024 · Abdera can optimize the delivery and therapeutic index of potent radioisotopes capable of emitting powerful alpha or beta particles to selectively destroy tumor cells while sparing healthy cells, providing patients with potentially transformative new cancer treatments.

Abdera’s differentiated approach to radiopharmaceutical drug discovery and development leverages the capabilities of our R adio O ptimized V ector E nginee r ing (ROVEr™) platform. We custom-engineer our medicines with tunable pharmacokinetic (PK) properties to achieve an ideal balance of tumor uptake and penetration while avoiding rapid ...

May 23, 2024 · Abdera can optimize the delivery and therapeutic index of potent radioisotopes capable of emitting powerful alpha or beta particles to selectively destroy tumor cells while sparing healthy cells, providing patients with potentially transformative new cancer treatments.

At Abdera Therapeutics, we are seeking curious and committed individuals who are ready for the opportunity to transform the way people living with cancer can be treated. We are relentless in our focus to offer new hope to families facing devastating diagnoses.

Aug 5, 2024 · Abdera’s Radio Optimized Vector Engineering (ROVEr™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells.